StockData
Moderna, Inc. logo

Moderna, Inc.

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)

Close on Nov 2, 2026Market cap $88.16BP/E –Yield –

Moderna Work in process inventory by Year

Work in process (drug substance & bulk formulated mRNA) inventory ($M) ($M)

Moderna Work in process inventory: $29M in FY2025, up 11.5% from a year earlier.

Latest, FY2025
29
Period ended Dec 31, 2025
Change on a year earlier
+11.5%
26 in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-Q (filed 2026-07-31) ↗

Reported in Form 10-Q / 10-K Note 6 (Inventory).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedWork in process (drug substance & bulk formulated mRNA) inventory ($M) ($M)Year on yearSource
FY2025Dec 31, 202529+11.5%Form 10-Q (filed 2026-07-31) ↗
FY2024Dec 31, 202426+73.3%Form 10-K (filed 2026-02-20) ↗
FY2023Dec 31, 202315-92.7%Form 10-K (filed 2025-02-21) ↗
FY2022Dec 31, 2022205-39.3%Form 10-K (filed 2024-02-23) ↗
FY2021Dec 31, 2021338+3,655.6%Form 10-K (filed 2023-02-24) ↗
FY2020Dec 31, 20209–Form 10-K (filed 2022-02-25) ↗

Cite this data

StockData. (2026). Moderna Work in process inventory ($M), annual FY2020–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/inv-wip

See every metric in the Moderna KPI table. Data updated Nov 3, 2026.